What changes in lipitor's market share post patent expiration?

Lipitor's market share fell sharply after its patent expired in November 2011. The drug had held nearly 100% of the atorvastatin market as the sole branded version, but once generic versions entered, patients and payers switched almost immediately to the cheaper copies.

What percentage did Lipitor's brand share drop to after generics launched?

Atorvastatin generics captured over 80% of prescriptions within weeks, leaving branded Lipitor with a small fraction of the original volume. Companies including Teva, Ranbaxy, and Watson began shipping low-cost versions the day after expiration. [1]

How did pricing affect the switch away from the brand?

Generic atorvastatin sold for about 80-90% less than branded Lipitor. Copays for generics stayed around $10 compared with $50 or higher for the brand. This price gap drove the rapid migration of patients who had previously kept using the branded product under insurance coverage. [1]

Why are companies challenging this patent?

No ongoing challenges remain. Lipitor's compound patent ended in November 2011, and several firms received FDA approval ahead of expiration to launch at-risk launches. The company paid Ranbaxy a settlement fee to delay its entry until November 2011, but other manufacturers entered once the time arrived. [1]

How does this drug compare with Keytruda?

Lipitor and Keytruda operate in completely different therapeutic areas. Lipitor is a daily statin for cholesterol management, while Keytruda is a quarterly or monthly oncology immunotherapy. Both products saw rapid market-share shifts once competitors arrived, but Keytruda's current exclusivity periods continue until roughly 2032. [1]

When does exclusivity expire?

The compound patent on atorvastatin expired November 30, 2011. Subsequent pediatric and method-of-use extensions had already expired by 2011, so no further exclusivity periods remained. [1]

Who makes the generics today?

Multiple companies supply generic atorvastatin today, including Pfizer itself through its established generics division. Pfizer now competes directly against other manufacturers such as Teva, Mylan, and Greenstone. [1]

Can biosimilars enter before patent expiry?

Lipitor is a small-molecule drug rather than a biologic, therefore biosimilars are unavailable. Small-molecule generics already entered after November 2011 and now occupy nearly all of the atorvastatin market. [1]

What side effects are patients asking about?

Patients still ask about muscle pain and liver enzyme changes that are associated with any atorvastatin product. The switch from brand to generic does not change the reported side effects, but some patients who previously used the branded version under insurance coverage now report lower copays and lower costs. [1]